, /PRNewswire/ -- The global hospital infection therapeutics market size is estimated to grow by .46 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.
27% during the forecast period. Increase in incidence and prevalence of respiratory disorders is driving market growth, with a trend towards increasing hospital visits. However, stringent regulations poses a challenge.
Key market players include Abbott Laboratories, AbbVie Inc., Achilles Therapeutics plc, AstraZeneca Plc, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Co.
, Cipla Inc., F. Hoffmann La Roche Ltd.
, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co.
Inc., Novartis AG, Pfizer Inc., Sanofi SA, Spero Therapeutics Inc.
, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
. Get a detailed analysis on regions, market segments, customer landscape, and companies- The global hospital infection therapeutics market is projected to expand due to the rising prevalence of chronic diseases and the increasing number of patient visits to hospitals. Central venous catheters, a leading cause of hospital-acquired infections (HAIs), are estimated to increase by 8% by 2025.
Intensive care units, with their high susceptibility to infections, are a significant source of these diseases. Sepsis, a common complication of hospital infections, is a leading cause of death in the US and , with over 600 and 1,500 f.
